Impact of screening between the ages of 60 and 64 on cumulative rates of cervical cancer to age 84y by screening history at ages 50 to 59: A population-based case-control study.
Cervical cancer
Cervical screening
Cumulative risk
Older women
Population rates
Screening older women
Screening over age 65
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
07
12
2020
revised:
12
05
2021
accepted:
16
05
2021
pubmed:
22
5
2021
medline:
29
6
2021
entrez:
21
5
2021
Statut:
ppublish
Résumé
There is little empirical data on the absolute benefit of cervical screening between ages 60-64y on subsequent cancer risk. We estimate the incidence of cervical cancer up to age 84y in women with and without a cervical cytology test at age 60-64y, by screening histories aged 50-59y. The current study is a population based case-control study of women born between 1928 and 1956 and aged 60-84y between 2007 and 2018. We included all such women diagnosed with cervical cancer in England and an aged-matched random sample without cancer. Women with a hysterectomy were excluded. Exposure was cervical cytology between ages 50-64y. The main outcome was 25y cumulative risk of cervical cancer between ages 60-84y. We found that eight in every 1000 (8.40, 95%CI: 7.78 to 9.07) women without a screening test between age 50-64y develop cervical cancer between the ages of 60-84y. The risk is half: 3.46 per 1000 (95%CI: 2.75 to 4.36) among women with a test between age 60-64y but no cervical screening test at age 50-59y. The absolute difference in risk is equivalent to one fewer cancer for every 202 such women screened. The highest risk (10.01, 95%CI:6.70 to 14.95) was among women with abnormal screening at ages 50-59y and no tests 60-64y. 25y risk among women with a screening test every five years between age 50-64y was just under two in a 1000 (1.59, 95%CI:1.42 to 1.78). Results suggest the upper age of screening should be dependent on previous screening participation and results.
Identifiants
pubmed: 34019928
pii: S0091-7435(21)00209-7
doi: 10.1016/j.ypmed.2021.106625
pmc: PMC8223500
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106625Subventions
Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Am J Epidemiol. 2014 May 1;179(9):1107-14
pubmed: 24685531
CA Cancer J Clin. 2012 May-Jun;62(3):147-72
pubmed: 22422631
PLoS Med. 2014 Jan;11(1):e1001585
pubmed: 24453946
Prev Med. 2018 Sep;114:188-192
pubmed: 29981791
Lancet Oncol. 2018 Dec;19(12):1569-1578
pubmed: 30392810
J Midlife Health. 2013 Jan;4(1):40-1
pubmed: 23833533
Int J Cancer. 2013 May 1;132(9):2134-40
pubmed: 22987437
Int J Cancer. 2018 Feb 15;142(4):709-718
pubmed: 29023748
Int J Cancer. 2020 Feb 1;146(3):617-626
pubmed: 30861114
J Med Screen. 2015 Dec;22(4):207-12
pubmed: 26346038
PLoS One. 2019 Mar 26;14(3):e0214486
pubmed: 30913262
BMJ. 2005 Apr 23;330(7497):938-9
pubmed: 15695496
PLoS Med. 2017 Oct 24;14(10):e1002414
pubmed: 29065127
BJOG. 2001 Apr;108(4):388-95
pubmed: 11305546